GT Biopharma, Inc. has released a statement from Vancouver, BC on December 19, 2025. According to Equity Insider News Commentary, the oncology industry is shifting towards platform-based precision treatments, leading to investors prioritizing companies developing multiple drugs over those with single-asset risk. This change underscores the increasing importance of diversified drug portfolios within the sector.